Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
about
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelorTicagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An UpdateModeling ligand recognition at the P2Y12 receptor in light of X-ray structural information.Structure of the human P2Y12 receptor in complex with an antithrombotic drugCase scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary interventionThe clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis.The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trialPharmacochemistry of the platelet purinergic receptors.Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.New aspects on efficient anticoagulation and antiplatelet strategies in sheep.A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD studyCost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome.Anti-platelet therapy: ADP receptor antagonists.Critical appraisal of ticagrelor in the management of acute coronary syndromeDiabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational studyTicagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisAntiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.Efficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis.Efficacy of enteral ticagrelor in hypothermic patients after out-of-hospital cardiac arrest.Perioperative management of patients on chronic antithrombotic therapyAbsolute bioavailability and regional absorption of ticagrelor in healthy volunteers.Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteersInverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.Effect of CYP3A4∗1G and CYP3A5∗3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.Ticagrelor for the treatment of arterial thrombosis.Review: Antiplatelet drugs: what comes next?Ticagrelor: from discovery to Phase III clinical trial.Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healing.Ticagrelor: a review of its use in the management of acute coronary syndromes.Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.Review of ticagrelor in the management of acute coronary syndromes.Safety profile and bleeding risk of ticagrelor compared with clopidogrel.Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
P2860
Q24605508-16B22AE8-EB41-4F43-809C-DF395E5803F8Q27006031-B73588A1-29B5-4029-A62A-C3A9E5C258F8Q27316009-89F5C39B-D22D-45AC-AF6B-734547F35B9CQ27682517-933C6F34-1DC1-48AB-A4FD-4E6032247A80Q30371026-E170DC8A-4D67-4AFE-811B-35B87847F4E6Q33699370-DFD3214B-728D-4D8E-BEB9-3C76B3D1418AQ33755410-EA6BE65C-5804-4278-8197-523D13EC499CQ33869922-2FFD3936-85F7-4CEF-8270-591689DEF9E5Q34805121-174B23C2-2031-4907-B364-0230C5C37D03Q35006714-2D0C27D5-8715-4B9F-AAF1-015ECA076E77Q35126038-1F9BE369-9B45-4095-83CF-12B3686058EDQ35216895-F4392786-5AE6-4771-8B35-476E568842AAQ35278165-DA58C0C9-B2C8-4704-AC41-67DAB825EFE2Q35660767-2347549D-9634-40CF-8754-3AD926D5183FQ35677083-82280933-9597-4E2D-86B6-F739C95F903CQ36062323-547B56D8-CD04-4B8B-BCA0-FD8D5EADA52CQ36160606-3F305706-49B4-4136-9B2E-6AB15939D589Q36237726-6D318AF6-F29B-4468-8EAB-5CB6972C5A0AQ36723877-B5F29E99-FAFA-495D-B74F-AD76970F2249Q36842832-D522665E-C195-4B4B-A92A-EEE787335D16Q37077147-F360BFA5-7E7A-4AFA-AD72-7ECF443597E8Q37259725-4FEF3701-78AD-486B-B065-EB612759B3B9Q37509443-DF4140D9-4E5F-4F71-9238-9E65D62723BCQ37685847-22F70AF2-BB55-481F-9293-EB025D8EA6BEQ37688144-67931BFF-D3D7-406A-B0C0-A86D4BB433E8Q37730915-BC2768CA-0F99-4517-B3BA-4D40A412AD41Q37779806-89267523-0A1F-4AA1-A7FD-4427D752B883Q37809630-EC5D1688-6095-4B4D-A35A-A265AC54FD88Q37818206-10E36722-4B52-44FA-B9C7-FE0355AF071BQ37868980-CF9A8561-250D-4F8F-ACCC-C2F95C81F043Q37875063-7E51C029-856A-46B3-893A-54D461237DB0Q37959155-B6EC3CE6-B1C3-4E01-94DD-C206E4CEC12CQ38001453-33BA7DF6-32EF-485D-B4E3-7824F4C5C0F3Q38018674-2926CA55-F51B-4502-BDDE-25BCB0734147Q38037672-D5B5AA2B-E395-46C7-80DE-D753E32D92C1Q38038255-C22E1176-0DFB-4370-A27A-AFE6FAFCADEFQ38040816-DB6625E0-5715-4FC5-B113-AD05114A8A1DQ38048837-6C0C8440-53BA-460B-9F5D-D8C3D0B30B28Q38053481-D7C0DD03-A480-40EE-A6AF-B05764C93CE6Q38065124-64EFCE6B-BFCD-4440-8922-0FFB510C9079
P2860
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
@en
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
@nl
type
label
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
@en
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
@nl
prefLabel
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
@en
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
@nl
P2860
P1476
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist
@en
P2093
J J J van Giezen
Steen Husted
P2860
P304
P356
10.1111/J.1755-5922.2009.00096.X
P577
2009-01-01T00:00:00Z